SCHEMBL2565474

SCHEMBL2565474

C#CCCNC(=O)CSc1nc2cc[nH]c2c(=O)n1-c1ccc(OCC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
USP2 O75604 3/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
TP53 P04637 7/20 0.46
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.46
TDP1 Q9NUW8 1/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2567954 0.92 KDM4E (0.53) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL13257406 0.90 KDM4E (0.54) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL3003973 0.84 KDM4E (0.45) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL2989209 0.83 KDM4E (0.44) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL2564092 0.83 KDM4E (0.43) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL2566922 0.82 KDM4E (0.44) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL3000433 0.79 ALDH1A1 (0.47) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL2569201 0.79 KDM4E (0.53) KDM4EPOLBRXFP1USP2CRHBP
SCHEMBL2564675 0.78 KMT2A (0.48) KDM4EPOLBRXFP1KMT2AMEN1
SCHEMBL2565418 0.78 MEN1 (0.46) KDM4EPOLBRXFP1USP2CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES KDM4E 2686/4885POLB 4165/4885RXFP1 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.